Wrong opinion: Flexibility on cancer drugs approval will foster innovation

I don't remember how I stumbled on an old article but it was enough to set me thinking about the "new drug approvals" process. I haven't changed the premise of the title ut prepended it with "the wrong opinion". The author exhorts to "shorten the approval process" and indirectly blaming the regulator for "delaying" the … Continue reading Wrong opinion: Flexibility on cancer drugs approval will foster innovation